Answers are grounded in this paper and cite their sources.
Introduction Myeloproliferative neoplasms (MPNs) are characterized by a TGFb-rich, fibrotic tumor microenvironment (TME), posing a challenge for targeted immunotherapies. Current treatments are largely palliative and do not selectively target MPN clones. In 1/3 of patients, MPNs are driven by mutant calreticulin (mutCALR), that binds to the thrombopoietin receptor (TpoR) causing activation and prominent display of the cancer neoantigen on the surface of TpoR-expressing cells - stem/progenitors (HSPCs) and megakaryocytes. Bispecific and inhibitory antibodies targeting mutCALR recently entered clinical trials. Here, we present pre-clinical validation of a pioneering chimeric antigen receptor T-cell (CAR-T) therapy targeting mutCALR, including efficacy in relevant clinical settings. Methods Killing efficacy and target cell TpoR expression was assessed by flow cytometry. To evaluate CAR-T in the relevant TME, we used scRNAseq to analyze iPSC-derived human bone marrow (BM) organoids co-engrafted with CAR-T, patient-derived CD34+ HSPCs +/- immunoregulatory factors abundant in the myelofibrotic niche (TGFβ and Galectin-1,Gal1). Results: The novel CAR-T demonstrated robust and highly selective eradication of low- and high- mutCALR expressing human cell lines in vitro, and CAR-T administration led to a dramatic reduction in leukemic burden and improved survival in NSG mice xenografted with mutCALR+ TpoR+ AML cells. Excellent BM infiltration of CAR-T, and near-complete ablation of leukaemia confirmed remarkable efficacy of CAR-T against mutCALR+ malignancies in vivo. CAR-T efficacy was tested on CD34+ HSPCs from MPN patients (n=12), including myelofibrosis, ET, and accelerated/blast phase MPN (AP/BP-MPN) with both ins5 and del52 variants (n=8) in 2D and 3D cultures. Excellent depletion of HSPCs (40->90%) and extreme specificity was observed, with minimal killing of JAK2V617F+ samples (n=4). Killing of AP/BP-MPN HSPCs was notably lower than chronic phase samples (myelofibrosis/ET), and correlated with lower surface TpoR expression. We hypothesized that treatment with TpoR agonists might increase TpoR expression on AP/BP-MPN HSPCs, by promoting megakaryocytic differentiation. Serial doses of rhTPO and TpoR agonists were tested. Pre-treatment of cells with Eltrombopag, but not with Romiplostim or rhTPO, increased surface TpoR expression by >50% and improved CAR-T killing, confirming that pharmacologically enhancing TpoR expression might boost vulnerability to anti-mutCALR immunotherapies. As expected, CAR-T killing efficacy was substantially diminished by prolonged exposure to JAK inhibitors at clinically-relevant concentrations, with a substantial drop in cytotoxicity and CAR-T proliferation. However, 24hr pre-incubation of CAR-T with peak plasma equivalent doses of JAK inhibitors prior to exposure to target cells led only to a smaller reduction in killing, ranging from <10-40%. Less potent JAK1 inhibitors demonstrating only a minor drop in efficacy, suggesting that selected JAKi agents/dosing regiments or short washout periods may be possible for synergistic co-therapy with CAR-T treatment Human organoids were used to evaluate CAR-T efficacy in the relevant TME. A scRNAseq dataset of 161,970 cells was generated from ‘healthy’ and ‘myelofibrotic’ (TGFb/Gal1 rich) organoids co-engrafted with CD34+ myelofibrosis HSPCs and CAR-Ts. CAR-Ts exposed to mutCALR+ primary cells had a 2-fold expansion of CD8+ effector memory cells. The proportion of immunosuppressive, regulatory T cells (Tregs) increased in a high TGFβ environment, but not with Gal1. GSEA showed significant enrichment in pathways associated with IFNγ, TNFa and IL-2 in CAR-Ts exposed to mutCALR+ samples. Ongoing analyses will evaluate vulnerability of specific patient HSPC/lineage subsets to CAR-T, the ability of healthy (non-mutant) haematopoiesis to reconstitute after treatment, and the impact of CAR-T killing on the BM niche. Conclusions: Here we present a novel CAR-T therapy showing potent and remarkably selective targeting of mutCALR-driven malignancies. This study also evaluates the impact of JAKi on CAR-T efficacy and presents the first use of human organoids to evaluate immunotherapies in the relevant human tissue environment, including features of the TME, validating this as a powerful platform for pre-clinical development of targeted therapies across blood cancers.
No takes yet. Share an insight, caveat, or question.
Rampotas et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: